

Contract No:Co2403079

Date:09/03/2024

## Letter of Authorization

**Manufacturer:** Atlas Medical GmbH  
Ludwig-Erhard-Ring 3,  
15827Blankenfelde-Mahlow, Germany  
Tel: +49 33 70 83 55 030  
Email: [amug@atlas-medical.com](mailto:amug@atlas-medical.com)

**Regulatory Office:** William James House, Cowley Road, Cambridge, CB4 0WX, UK  
Tel: +44 1223 858 910  
Fax: +44 1223 858 524  
Email: [info@atlas-site.co.uk](mailto:info@atlas-site.co.uk)

**Middle East Site:** Sahab Free Zone Area  
P. O. Box 204, Amman 11512, Jordan.  
Tel.: +962 6 4026468  
Fax: +962 6 4022588  
Email: [info@atlas-medical.com](mailto:info@atlas-medical.com)


**Agent:** San Medico  
Republic of Moldova, city Chisina  
+37368228890

Atlas Medical, hereby appoint the above mentioned agent to import, register and distribute Atlas Medical Products in Moldova

**Appointment Conditions:**

1. This appointment is valid for 3 year from the above mentioned date.
2. Either Party can cancel this appointment by giving the other party a 60 day notice.

On behalf of the Manufacturer  
General Manager  
Haya Amawi



---

Atlas Medical: Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Germany. Tel: +49 33 70 83 55 030  
Regulatory Office: William James House, Cowley Road, Cambridge, CB4 0WX, UK. Tel: +44 1223 858 910  
Middle East Site : King Abdullah the Second Industrial Estate, Street 19, Sahab Free Zone Area, P.O. Box: 204, Amman 11512, Jordan

**GMED certifie que le système de management de la qualité développé par**  
*GMED certifies that the quality management system developed by*

**ATLAS MEDICAL GmbH**  
**Ludwig-Erhard-Ring 3**  
**15827 Blankenfelde-Mahlow GERMANY**

**pour les activités**  
*for the activities*

**Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic in vitro .**

*Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices.*

**réalisées sur le(s) site(s) de**  
*performed on the location(s) of*

**Voir addendum**

*See addendum*

**est conforme aux exigences des normes internationales**  
*complies with the requirements of the international standards*

**ISO 13485: 2016**

**Début de validité / Effective date October 9th, 2023 (included)**

**Valable jusqu'au / Expiry date : October 8th, 2026 (included)**

**Etabli le / Issued on : October 9th, 2023**




**CERTIFICATION  
DE SYSTEMES  
DE MANAGEMENT**  
Accréditation n°4-0608  
Liste des sites accrédités  
et portée disponible sur  
[www.cofrac.fr](http://www.cofrac.fr)

GMED N° 36655-2

Ce certificat est délivré selon les règles de certification GMED / This certificate is issued according to the rules of GMED certification

Renouvelle le certificat 36655-1



**On behalf of the President**  
**Béatrice LYS**  
**Technical Director**

**GMED • Société par Actions Simplifiée au capital de 300 000 € • Organisme Notifié/Notified Body n° 0459**  
**Siège social : 1, rue Gaston Boissier - 75015 Paris • Tél. : 01 40 43 37 00 • [gmed.fr](http://gmed.fr)**

**Ce certificat couvre les activités et les sites suivants :**  
*This certificate covers the following activities and sites:*

**French version :**

**Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic *in vitro* à usage professionnel et/ ou d'autodiagnostic, dans les domaines du groupage sanguin, de la microbiologie, de la biochimie, de la toxicologie, de l'oncologie, de la cardiologie, de l'histologie, de l'endocrinologie et des maladies infectieuses, dans les techniques d'Agglutination/ ELISA/ Tests rapides/ Colorimétrie/ Disques antibiotiques.**

**English version:**

*Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices for professional use and/or for self-testing, in the field of Immunohematology, Microbiology, Biochemistry, Toxicology, Oncology, Cardiology, Histology, Endocrinology Biosensors and Infectious diseases, in techniques of Agglutination/ ELISA/ Rapid tests/ Colorimetry/Antibiotic disks.*

**ATLAS MEDICAL GmbH  
Ludwig-Erhard-Ring 3  
15827 Blankenfelde-Mahlow  
GERMANY**

French version:

**Siège social, responsable de la mise sur le marché**

*English version:*

*Headquarter, legal manufacturer*

\*\*\*\*\*

**Sahab Industrial Zone Area  
King Abdullah II Industrial City  
Amman 11512  
JORDAN**

French version:

**Conception, fabrication et contrôle final**

*English version:*

*Design, manufacture and final control*

\*\*\*\*\*

**2 sites / 2 sites**

DocuSigned by:  
*Beatrice Lys*  
FF33BDA88AA04A3...  
**GMED**  
GROUPE LNE

**On behalf of the President  
Béatrice LYS  
Technical Director**

Declaration Ref No: DC21-0035

## **CE Declaration of Conformity**

**According to Annex III of the IVD Directive 98/79/EC**

We,

**Atlas Medical**

Head office: Ludwig-Erhard-Ring 3  
Blankenfelde-Mahlow, Germany.  
Tel: +49 - 33708 – 3550 30  
Email: [info@atlas-medical.com](mailto:info@atlas-medical.com)

Middle East Site: Sahab Free Zone Area, P. O. Box 212555, Amman, Jordan.  
Tel.: +962 6 4026468  
Fax: +962 6 4022588  
Email: [info@atlas-medical.com](mailto:info@atlas-medical.com)

Declare our responsibility that the following product:


**See Attached list**


- Comply with all essential requirements (Annex I) of the IVD Directive 98/79/EC. This compliance has been properly documented and covers the items listed in Annex I of the IVD Directive.
- This product is produced under Atlas quality system (ISO13485:2016) issued by GMED:  
**Certificate N°:** 36655 rev 1  
**Expiry Date:** October 8<sup>th</sup>.2023
- Comply with the essential requirements of following standards (EN 18113-1, -2, -4:2011, EN ISO 15223:2016, EN ISO 23640:2015, EN ISO 14971:2019, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002).

And

Intended for In-Vitro Professional use only.

**Manufacturer**  
**Atlas Medical**  
**Ludwig-Erhard-Ring 3**  
**Blankenfelde-Mahlow , Germany.**



|               |            |                |                                                                                      |                           |
|---------------|------------|----------------|--------------------------------------------------------------------------------------|---------------------------|
| Atlas Medical | Issue date | Date of review | Management approval                                                                  | MRXDO10F.10<br>08.02.2011 |
|               | March.2021 | 09.03.2021     |  |                           |

## CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

| Product Description                                                                                                                                                                                                                                                                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 8.00.02.0.0100 : ASO Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls).                                                                                                                                                                                                                  |
| 8.00.00.0.0100: CRP Latex Kit, 100 Tests (4 ml Latex, 2x1.0 ml Controls)                                                                                                                                                                                                                  |
| 8.00.04.0.0100: RF Latex Kit, 100 Tests (4ml Latex, 2x1.0ml controls)                                                                                                                                                                                                                     |
| 8.00.17.0.0100: D-Dimer Latex Kit, 100 Tests                                                                                                                                                                                                                                              |
| 8.00.13.0.0300 : Streptococcus Latex Kit, 6 Groups, 6x50 Tests (5x1.5ml Latex (A,B,C,G,F), 1x3ml Latex(D), 1x1.0ml Positive Control, 1x2ml Extraction Reagent E, 1x1.5ml Extraction Reagent 1, 1x1.5ml Extraction Reagent 2, 2x2.5ml Extraction Reagent 3, Stirring Sticks, Glass Slide). |
| 8.00.18.3.0500 : RPR Syphilis (Coarse Grain) Kit, 500 Tests (10 ml latex, 2x1ml control) Without card, stirring sticks.                                                                                                                                                                   |
| 8.00.18.3.1000 RPR Carbon Antigen (Coarse Grain) Kit, 1000 Tests (Reagent only).                                                                                                                                                                                                          |



## ASO LATEX KIT

**IVD** For in -*vitro* diagnostic and professional use only



Store at 2-8°C.



### INTENDED USE

ATLAS ASO latex Test is used for the qualitative and semi-quantitative measurement of antibodies to Antistreptolysin-O in human serum.

### INTRODUCTION

The group A  $\beta$ -hemolytic streptococci produce various toxins that can act as antigens. One of these exotoxins streptolysin-O, was discovered by Todd in 1932.

A person infected with group A hemolytic streptococci produces specific antibodies against these exotoxins, one of which is antistreptolysin-O. The quantity of this antibody in a patient's serum will establish the degree of infection due to the hemolytic streptococcal.

The usual procedure for the determination of the antistreptolysin titer is based on the inhibitory effect that the patient's serum produces on the hemolytic power of a pre-titrated and reduced streptolysin-O. However, the antigen-antibody reaction occurs independently of the hemolytic activity of streptolysin-O. This property enables the establishment of a qualitative and quantitative test for the determination of the antistreptolysin-O by agglutination of latex particles on slide.

### PRINCIPLE

ASO test method is based on an immunologic reaction between streptococcal exotoxins bound to biologically inert latex particles and streptococcal antibodies in the test sample. Visible agglutination occurs when increased antibody level is present in the test specimen.

### MATERIALS

#### MATERIALS PROVIDED

- ASO Latex Reagent: Latex particles coated with streptolysin O, pH, 8.2. Preservative.
- ASO Positive Control (Red cap): Human serum with an ASO concentration > 200 IU/mL. Preservative.
- ASO Negative Control (Blue cap) Animal serum. Preservative
- Glass Slide.
- Stirring Sticks.

**Note:** This package insert is also used for individually packed reagent.

#### MATERIALS REQUIRED BUT NOT PROVIDED

- Mechanical rotator with adjustable speed at 80-100 r.p.m.
- Vortex mixer.
- Pippetes 50  $\mu$ L.
- Glycine Buffer 20x (1000 mmol/l): add one part to nineteen parts of distilled water before use.

#### Packaging contents

**REF** 8.00.02.0.0100 (1x4ml Latex Reagent, 1x1ml positive control, 1x1ml negative control)

#### PRECAUTIONS

- All reagents contain 0.1 %(w/v) sodium azide as a preservative.
- Protective clothing should be worn when handling the reagents.
- Wash hands and the test table top with water and soap once the testing is done.
- Reagents containing sodium azide may be combined with copper and lead plumbing to form highly explosive metal azides. Dispose of reagents by flushing with large amounts of water to prevent azide buildup.
- For In Vitro diagnostic use.
- Components prepared using human serum found negative for hepatitis B surface antigen (HBsAg), HCV and antibody to HIV (1/2) by FDA required test. However, handle controls as if potentially infectious.
- Accuracy of the test depends on the drop size of the latex reagent (40 $\mu$ l). Use only the dropper supplied with latex and hold it perpendicularly when dispensing.
- Use a clean pipette tip and stirring stick for each specimen, and glass slides should be thoroughly rinsed with water and wiped with lint-free tissue after each use.
- Check reactivity of the reagent using the controls provided.
- Do not use these reagents if the label is not available or damaged.
- Do not use the kit if damaged or the glass vials are broken or leaking and discard the contents immediately.
- Test materials and samples should be discarded properly in a biohazard container.

#### REAGENT PREPARATION:

The ASO Latex reagent is ready to use. No preparation is required. Mix gently before use to ensure a uniform suspension of particles.

#### STORAGE AND STABILITY

- Reagents are stable until specified expiry date on bottle label when stored refrigerated (2-8°C).
- **DO NOT FREEZE.**
- The ASO Latex Reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.
- Always keep vials in vertical position. If the position is changed, gently mix to dissolve aggregates that may be present.
- Reagents deterioration: Presence of particles and turbidity.

#### SAMPLES

- Use fresh serum collected by centrifuging clotted blood.
- If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8°C and for 3 months at -20°C.
- Samples with presence of fibrin should be centrifuged before testing. Do not use highly hemolyzed or lipemic samples.
- **DO NOT USE PLASMA.**

#### PROCEDURE

##### Qualitative method

1. Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
2. Place (40  $\mu$ L) of the sample and one drop of each Positive and Negative controls into separate circles on the slide test.
3. Mix the ASO-latex reagent vigorously or on a vortex mixer before using and add one drop (40  $\mu$ L) next to the sample to be tested.
4. Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample.
5. Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes. False positive results could appear if the test is read later than two minutes.

##### Semi-quantitative method

1. Make serial two-fold dilutions of the sample in 9 g/L saline solution.

2. Proceed for each dilution as in the qualitative method.

#### QUALITY CONTROL

- Positive and Negative Controls should be included in each test batch.
- Acceptable performance is indicated when a uniform milky suspension with no agglutination is observed with the ASO Negative Control and agglutination with large aggregates is observed with the ASO Positive Control.

#### CALCULATIONS

The approximate ASO concentration in the patient sample is calculated as follows:

$$200 \times \text{ASO Titer} = \text{IU/mL}$$

#### READING AND INTERPRETATION

Examine macroscopically the presence or absence of visible agglutination immediately after removing the slide from the rotator. The presence of agglutination indicates an ASO concentration equal or greater than 200 IU/mL. The titer, in the semi-quantitative method, is defined as the highest dilution showing a positive result.

#### REFERENCE VALUES

Up to 200 IU/mL (adults) and 100 IU/mL (children < 5 years old). Each laboratory should establish its own reference range.

#### PERFORMANCE CHARACTERISTICS

##### Analytical sensitivity:

200 (±50) IU/mL.

##### PROZONE EFFECT

No prozone effect was detected up to 1500 IU/mL.

##### SENSITIVITY

98%.

##### SPECIFICITY

97%.

#### INTERFERENCES

##### NON-INTERFERING SUBSTANCES:

- Hemoglobin (10 g/L)
- Bilirubin (20 mg/dL)
- Lipids (10 g/L)
- Rheumatoid factors (300 IU/mL)
- Other substances may interfere.

#### LIMITATIONS

- Reaction time is critical. If reaction time exceeds 2 minutes, drying of the reaction mixture may cause false positive result.
- Freezing the ASO Latex Reagent will result in spontaneous agglutination.

- Intensity of agglutination is not necessarily indicative of relative ASO concentration; therefore, screening reactions should not be graded.
- False positive results may be obtained in conditions such as, rheumatoid arthritis, scarlet fever, tonsillitis, several streptococcal infections and healthy carriers.
- Early infections and children from 6 months to 2 years may cause false negative results. A single ASO determination does not produce much information about the actual state of the disease.
- Titrations at biweekly intervals during 4 or 6 weeks are advisable to follow the disease evolution.
- Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

#### REFERENCES

1. Haffejee . Quarterly Journal of Medicine 1992. New series 84; 305: 641-658.
2. Ahmed Samir et al. Pediatric Annals 1992; 21: 835-842.
3. Spaun J et al. Bull Wld Hlth Org 1961; 24: 271-279.
4. The association of Clinical Pathologists 1961. Broadsheet 34.
5. Picard B et al. La Presse Medicale 1983; 23: 2-6.
6. Klein GC. Applied Microbiology 1971; 21: 999-1001.
7. Young DS. Effects of drugs on clinical laboratory test, 4th ed. AACC Press, 1995.

 **ATLAS Medical GmbH**  
**Ludwig-Erhard Ring 3**  
**15827 Blankenfelde-Mahlow**  
**Germany**  
**Tel: +49 - 33708 – 3550 30**  
**Email: [info@atlas-medical.com](mailto:info@atlas-medical.com)**  
**Website: [www.atlas-medical.com](http://www.atlas-medical.com)**

**PPI2325A01**

**Rev A (05.01.2023)**

|                                                                                     |                                                     |                                                                                     |                                    |
|-------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------|
|  | Catalogue Number                                    |  | Temperature limit                  |
|  | In Vitro diagnostic medical device                  |  | Caution                            |
|  | Contains sufficient for <n> tests and Relative size |  | Consult instructions for use (IFU) |
|  | Batch code                                          |  | Manufacturer                       |
|  | Fragile, handle with care                           |  | Use-by date                        |
|  | Manufacturer fax number                             |  | Do not use if package is damaged   |
|  | Manufacturer telephone number                       |  | Date of Manufacture                |
|  | Keep away from sunlight                             |  | Keep dry                           |
|  | Positive control                                    |  | Negative control                   |

## RF LATEX KIT



For In-Vitro diagnostic and professional use only

2°C 8°C  
Store at 2-8°C



### INTENDED USE

Atlas RF latex test for the qualitative and semi-quantitative measurement of RF in human serum.

### INTRODUCTION

Rheumatoid factors (RF) are antibodies directed against antigenic sites in the Fc fragment of human and animal IgG. Their frequent occurrence in rheumatoid arthritis makes them useful for diagnosis and monitoring of the disease.

One method used for rheumatoid factor detection is based on the ability of rheumatoid arthritis sera to agglutinate sensitized sheep red cells, as observed by Waaler and Rose. A more sensitive reagent consisting of biologically inert latex beads coated with human gamma globulin was later described by Singer and Plotz. The RF kit is based on the principle of the latex agglutination assay of Singer and Plotz. The major advantage of this method is rapid performance (2-minutes reaction time) and lack of heterophile antibody interference.

### PRINCIPLE

The RF reagent is based on an immunological reaction between human IgG bound to biologically inert latex particles and rheumatoid factors in the test specimen. When serum containing rheumatoid factors is mixed with the latex reagent, visible agglutination occurs.

### MATERIALS

#### MATERIALS PROVIDED

- RF Latex Reagent: Latex particles coated with human gamma globulin, pH, 8.2. Preservative.
- RF Positive Control Serum (Red Cap): Human serum with a RF concentration > 30 IU/ML. Preservative.
- \*RF Negative Control (Blue Cap): Non-reactive buffer containing BSA and 0.1% sodium azide.
- \*Glycine Buffer 20X (1000 mmol/L) (Optional): add one part to nineteen parts of distilled water before use.
- \*Black glass Slide
- Stirring sticks

**NOTE: This package insert is also used for individually packed reagent.**

#### MATERIALS REQUIRED BUT NOT PROVIDED

- Mechanical rotator with adjustable speed at 80-100 r.p.m.
- Pipettes 50 µL
- \*9 g/L saline.

### Packaging contents



**8.00.04.0.0100 (1x4ml Latex Reagent, 1x1ml positive control, 1x1ml negative control)**

### PRECAUTIONS

- \*For in vitro diagnostic and professional use only. The test is not for near-patient or self-testing.
- All reagents contain 0.1 % (w/v) sodium azide as a preservative.
- Protective clothing should be worn when handling the reagents.
- Wash hands and the test table top with water and soap once the testing is done.
- Reagents containing sodium azide may be combined with copper and lead plumbing to form highly explosive metal azides. Dispose of reagents by flushing with large amounts of water to prevent azide buildup.
- Components prepared using human serum found negative for hepatitis B surface antigen (HBsAg), HCV and antibody to HIV (1/2) by FDA required test. However, handle controls as if potentially infectious.
- Accuracy of the test depends on the drop size of the latex reagent \*(35µL ±5µL). Use only the dropper supplied with latex and hold it perpendicularly when dispensing.
- Use a clean pipette tip and stirring stick for each specimen, and glass slides should be thoroughly rinsed with water and wiped with lint-free tissue after each use.
- Check reactivity of the reagent using the controls provided.
- Do not use these reagents if the label is not available or damaged.
- Do not use the kit if damaged or the glass vials are broken or leaking and discard the contents immediately.
- Test materials and samples should be discarded properly in a biohazard container.
- \*Components from human origin have been tested and found to be negative for the presence of HBsAg, HCV, and antibody to HIV (1/2). However, handle cautiously as potentially infectious.
- \*Wash the area of contact with water immediately if contact occurs.
- \*Do not drink or ingest the reagent.
- \*Do not use the reagent if the label is missing, damaged, or unclear.
- \*Do not use white or transparent glass slides during testing.
- \*Perform the test in a well-lit area with good visibility.
- \*Close the vial after each test.
- \*Failure in following the instructions may give incorrect results or face safety hazards.
- \*Handle the used disinfectant with care.
- \*Any serious incident that occur in relation to the device shall be reported to the manufacturer and the competent authority. (Feedback@atlas-medical.com)

#### REAGENT PREPARATION:

- The RF Latex reagent is ready to use. No preparation is required. Mix gently before use to ensure a uniform suspension of particles.

#### STORAGE AND STABILITY

- Reagents are stable until specified expiry date on bottle label when stored refrigerated (2-8°C).
- Do not freeze.

- Always keep vials in vertical position. If the position is changed, gently mix to dissolve aggregates that may be present.
- The RF latex reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.
- Reagents deterioration: Presence of particles and turbidity.

#### SPECIMEN COLLECTION AND STORAGE

- Use fresh serum collected by centrifuging clotted blood.
- If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8°C and for 3 months at -20°C.
- Samples with presence of fibrin should be centrifuged before testing. Do not use highly hemolyzed or lipemic samples.
- Do not use PLASMA.

#### PROCEDURE

##### Qualitative method

1. Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
2. Place (40 µL) of the sample and one drop of each Positive and Negative controls into separate circles on the slide test.
3. \*Swirl the reagent gently before use and add one drop (35 µL ±5µL) next to the sample to be tested.
4. \*Close the vial tightly after use.
5. Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample.
6. Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes. False positive results could appear if the test is read later than two minutes.

##### \*Semi-quantitative method

Prepare serial two-fold dilutions of the sample in 9 g/L saline/glycine buffer (1X):

1. Allow the reagents and samples to reach room temperature.
2. Add (40 µL) of 9 g/L saline/glycine buffer (1X) into 6 circles of the black glass slide.
3. Add (40 µL) of the serum sample to the first circle.
4. Mix well using the pipette and then transfer (40 µL) from the first circle to the second circle, repeat until finishing the six circles.
5. Swirl the reagent vial.
6. Add one drop of RF reagent (35µL ±5µL) next to the samples in each circle.
7. Close the reagent vial.
8. Mix the drops with a stirrer, spreading them over the entire surface of the circle.
9. Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes.

READING AND INTERPRETATION

Examine macroscopically the presence or absence of visible agglutination immediately after removing the slide from the rotator. The presence of agglutination indicates a RF concentration equal or greater than 8 IU/mL (Note 1).  
The titer, in the semi-quantitative method, is defined as the highest dilution showing a positive result.

CALCULATIONS

The approximate RF concentration in the patient sample is calculated as follows:

8 x RF Titer = IU/mL

QUALITY CONTROL

- Positive and Negative controls are recommended to monitor the performance of the procedure, as well as a comparative pattern for a better result interpretation.
- All result different from the negative control result, will be considered as a positive.

PERFORMANCE CHARACTERISTICS

Analytical sensitivity

8 (6-16) IU/ml, under the described assay conditions.

PROZONE EFFECT

No prozone effect was detected up to 1500 IU/ml.

DIAGNOSTIC SENSITIVITY

100%.

DIAGNOSTIC SPECIFICITY

100%.

The diagnostic sensitivity and specificity have been obtained using 139 samples compared with the same method of a competitor.

\*PRECISION

100%.

INTERFERENCES

NON-INTERFERING SUBSTANCES:

- Hemoglobin (10g/L)
- Bilirubin (20mg/dl)
- Lipids (10g/L)

Other substances may interfere.

LIMITATIONS

- Reaction time is critical. If reaction time exceeds 2 minutes, drying of the reaction mixture may cause false positive result.
- Freezing the RF Latex Reagent will result in spontaneous agglutination.
- Intensity of agglutination is not necessarily indicative of relative RF concentration; therefore, screening reactions should not be graded.
- Increased levels of RF may be found in some diseases other than rheumatoid arthritis such as infectious mononucleosis, sarcoidosis, lupus erythematosus, Sjogren’s syndrome.
- Certain patients with rheumatoid arthritis will not have the RF present in their serum.

- The incidence of false positive results is about 3-5 %. Individuals suffering from infectious mononucleosis, hepatitis, syphilis as well as elderly people may give positive results.
- Diagnosis should not be solely based on the results of latex method but also should be complemented with a Waaler Rose test along with the clinical examination.

REFERENCE VALUES

Up to 8 IU/mL. Each laboratory should establish its own reference range.

NOTES

1. Results obtained with a latex method do not compare with those obtained with Waaler Rose test. Differences in the results between methods do not reflect differences in the ability to detect rheumatoid factors.

REFERENCES

1. Robert W Dorner et al. Clinica Chimica Acta 1987; 167: 1 – 21.
2. Frederick Wolfe et al. Arthritis and Rheumatism 1991; 34: 951- 960.
3. Robert H Shmerling et al. The American Journal of Medicine 1991; 91: 528 –534.
4. Adalbert F. Schubart et al. The New England Journal of Medicine 1959; 261: 363 – 368.
5. Charles M. Plotz 1956; American Journal of Medicine; 21:893 – 896.
6. Young DS. Effects of drugs on clinical laboratory test, 4th ed. AACC Press, 1995.

 **ATLAS Medical GmbH**  
**Ludwig-Erhard Ring 3**  
**15827 Blankenfelde-Mahlow**  
**Germany**  
**Tel: +49 - 33708 – 3550 30**  
**Email: [Info@atlas-medical.com](mailto:Info@atlas-medical.com)**  
**Website: [www.atlas-medical.com](http://www.atlas-medical.com)**

PPI2326A01

Rev B (30.03.2024)

|                                                                                     |                                                     |                                                                                     |                                    |
|-------------------------------------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------|
|  | Catalogue Number                                    |  | Temperature limit                  |
|  | In Vitro diagnostic medical device                  |  | Caution                            |
|  | Contains sufficient for <n> tests and Relative size |  | Consult instructions for use (IFU) |
|  | Batch code                                          |  | Manufacturer                       |
|  | Fragile, handle with care                           |  | Use-by date                        |
|  | Manufacturer fax number                             |  | Do not use if package is damaged   |
|  | Manufacturer telephone number                       |  | Date of Manufacture                |
|  | Keep away from sunlight                             |  | Keep dry                           |
|  | Positive control                                    |  | Negative control                   |

**\*: Indication of the introduced modifications.**



## CRP LATEX KIT

**IVD** For *in vitro* diagnostic and professional use only

2°C  8°C Store at 2-8°C. 

### INTENDED USE

Atlas CRP Latex kit is a manual slide latex agglutination test for the qualitative and semi-quantitative detection of C-reactive protein (CRP) in human serum to aid in the diagnosis of individuals with suspected inflammation.

### INTRODUCTION

C-reactive protein (CRP) is an evolutionarily conserved constitutive protein produced primarily by hepatocytes in minute amounts. At baseline levels, CRP mediates important biological functions. Its clinical significance as a component of the acute phase response emerged upon linking elevated blood levels of CRP to trauma, infection and inflammatory non-infectious disorders including autoimmune diseases. Its concentration can increase up to 1000-fold in severe inflammatory insults. CRP quickly rises in blood upon the onset of an acute stimulus (within 6 hours), and may double every 8 hours reaching a peak at 50 hours. Likewise, blood CRP rapidly drops upon cessation of the stimulus in an exponential manner. Although non-discriminatory of the root cause, elevated serum CRP has been established as an important marker of inflammation.

### PRINCIPLE

The C-Reactive Protein test is based on the principle of the latex agglutination. When latex particles complexed with human anti-CRP are mixed with a patient's serum containing C- reactive protein, a visible agglutination reaction will take place within 2 minutes.

### KIT COMPONENTS

#### Materials Provided

- **CRP Latex Reagent:** Latex particles coated with goat IgG anti-human CRP (approximately 1 %), pH 7.4. **MIX WELL BEFORE USE.**
- **CRP Positive Control (Red Cap):** Diluted human serum with CRP concentration > 20mg/L.
- **CRP Negative Control (Blue Cap):** Non-reactive buffer containing BSA and 0.1% sodium azide.
- **Glycine Buffer 20X (1000 mmol/L) (Optional):** add one part to nineteen parts of distilled water before use.
- **Black Glass Slide.**
- **Stirring Sticks.**

- **Package insert.**

**NOTE:** This package insert is also used for individually packed reagent.

#### Materials Required But Not Provided

- Mechanical rotator with adjustable speed at 80-100 r.p.m.
- Calibrated 50 µL micro-pipette.
- 9 g/L saline.

#### Packaging Contents

**REF 8.00.00.0.0100 (1x4ml Latex Reagent, 1x1ml positive control, 1x1ml negative control)**

#### REAGENT STORAGE AND STABILITY

- Reagents are stable until specified expiry date on vial label when stored refrigerated (2 - 8°C).
- **DO NOT FREEZE.**
- The CRP latex reagent, once shaken must be uniform without visible clumping. When stored refrigerated, a slight sedimentation may occur and should be considered normal.
- Do not use the latex reagent or controls if they become contaminated.
- Always keep vials in a vertical position. If the position is changed, gently mix to dissolve aggregates that may be present.
- Reagent deterioration: Presence of particles and turbidity.

#### PRECAUTIONS AND WARNINGS

- For *in vitro* diagnostic and professional use only. The test is not for near-patient or self-testing.
- All reagents contain 0.1% (w/v) Sodium azide as a preservative.
- Protective clothing should be worn when handling the reagents.
- Wash hands and the test table top with water and soap once the testing is done.
- This kit is NOT to be used in CRP-guided therapy.
- Components containing human serum were tested for hepatitis B surface antigen (HBsAg), HCV and antibody to HIV (1/2) as required by FDA; and found to be negative. However, handle controls as if potentially infectious.
- Accuracy of the test depends on the drop size of the latex reagent (35 µL ±5µL). Use only the dropper supplied with latex and hold it perpendicularly when dispensing.
- Use a clean pipette tip and stirring stick for each specimen, and glass slides should be thoroughly rinsed with water and wiped with lint-free tissue after each use.
- Check reactivity of the reagent using the controls provided.
- Do not use these reagents if the label is not available or damaged.
- Do not use the kit if damaged or the glass vials are broken or leaking and discard contents immediately.

- Test materials and samples should be discarded properly in a biohazard container.
- Use forceps, scoops, or other mechanical devices for removing broken glass from the working area. A dustpan and brush should be used to clean up shards/small pieces of broken glass. Broken glass must be disposed of in a sharps container
- Wash the area of contact with water immediately if contact occurs.
- failure in following the instructions may give incorrect results or incur safety hazards
- Handle the used disinfectant with care.
- Close the vial after each test.
- Perform the test in a well-lit area with good visibility.
- Do not use white or transparent glass slides during testing.
- Do not touch, drink, or ingest the reagent.
- Certain nutritional supplements may effect on CRP levels.
- Any serious incident that occur in relation to the device shall be reported to the manufacturer and the competent authority. (Feedback@atlas-medical.com)

#### COLLECTION, HANDLING AND PREPARATION OF SPECIMEN

- Use fresh serum collected by centrifuging clotted blood.
- Samples with presence of fibrin should be centrifuged before testing. Do not use highly hemolyzed or lipemic samples.
- **Do not use plasma.**

#### SPECIMEN STORAGE AND STABILITY

If the test cannot be carried out on the same day, store the specimen for 7 days at 2-8°C and for 3 months at -20°C. Frozen samples should be completely thawed and brought to room temperature before testing. Avoid repeated freezing and thawing of the samples.

#### REAGENT PREPARATION

The CRP Latex reagent is ready to use. No preparation is required. Mix gently before use to ensure a uniform suspension of particles.

#### PROCEDURE

**NOTE: The latex and sample volumes are very critical for correct test performance. Please adhere to the volumes stipulated in this package insert.**

#### QUALITATIVE TEST:

1. Allow the reagents and samples to reach room temperature. The sensitivity of the test may be reduced at low temperatures.
2. Place (40 µL) of the sample and one drop (40 µL ±5µL) of each Positive and Negative controls into separate circles on the slide test.
3. Swirl the CRP latex reagent gently and add one drop (35 µL

±5µL) next to the samples and controls to be tested.

4. Close the reagent vial tightly.
5. Mix the drops with a stirrer, spreading them over the entire surface of the circle. Use different stirrers for each sample and each control.
6. Place the slide on a mechanical rotator at 80-100 r.p.m. for **2 minutes**. False positive results could be obtained if the test is read later than two minutes.

#### B. SEMI-QUANTITATIVE TEST:

Prepare serial two-fold dilutions of the sample in 9 g/L saline/glycine buffer (1X):

1. Allow the reagents and samples to reach room temperature.
2. Add (40 µL) of 9 g/L saline/glycine buffer (1X) into 6 circles of the black glass slide.
3. Add (40 µL) of the serum sample to the first circle.
4. Mix well using the pipette and then transfer (40 µL) from the first circle to the second circle, repeat until finishing the six circles.
5. Swirl the reagent vial.
6. Add one drop of CRP reagent (35µL ±5µL) next to the samples in each circle.
7. Close the reagent vial.
8. Mix the drops with a stirrer, spreading them over the entire surface of the circle.
9. Place the slide on a mechanical rotator at 80-100 r.p.m. for 2 minutes.

#### CALCULATIONS

The approximate CRP concentration in the patient sample is calculated as follows:

$$\text{Sensitivity} \times \text{CRP Titer} = \text{mg/L}$$

(Sensitivity indicated on the label of the latex vial)

#### INTERPRETATION OF THE RESULT

Examine macroscopically the presence or absence of visible agglutination immediately after stopping the rotator.

The presence of agglutination indicates a CRP concentration equal or greater than the reagent sensitivity (mg/L CRP) (indicated on the label of the latex vial).

The titer, in the semi-quantitative method, is defined as the highest dilution showing a positive result.

#### REFERENCE VALUES

Each laboratory should establish its own reference range.

#### QUALITY CONTROL

- Positive and Negative controls are recommended to monitor the performance of the kit, as well as providing a comparative pattern for better result interpretation.
- Any result that differs from the negative control result is considered positive.

#### LIMITATIONS OF THE TEST

- Reaction time is critical. If reaction time exceeds two (2) minutes, the reaction mixture may dry causing particles, which can be mistaken for false positive results.
- Freezing the CRP Latex Reagent will result in spontaneous agglutination.
- Intensity of agglutination is not necessarily indicative of relative CRP concentration; therefore, reactions should not be graded.
- A false negative can be attributed to a prozone phenomenon (antigen excess). It is recommended, therefore, to check all suspected negative sera by retesting with a 1:10 dilution in 9 g/L saline/glycine buffer (1X).

#### PERFORMANCE CHARACTERISTICS

- **Sensitivity:** 6 mg/L.
- **Prozone effect:** No prozone effect was detected up to 1600 mg/L.
- **Diagnostic sensitivity:** 100 % in comparison with a commercial latex kit.
- **Diagnostic specificity:** 100 % in comparison with a commercial latex kit.
- **Precision : 100%**
- **Interferences:**  
No interference was observed with the following substances at the concentrations indicated:
  - Hemoglobin (<15 g/dl)
  - Bilirubin (<20 mg/dl)
  - Lipids (<13 g/dL)
  - Other substances interfere, such as RF (>75IU/ml).

#### NOTES

- Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

#### REFERENCES

- Pepys, M.B.. Lancet 1:653 (1981).
- Werner, M.. Clin.Chem. Acta 25:299 (1969).
- MacLeod, C.M., et. al.. J. Exp. Med 73:191 (1941).
- Wood, HF., et. al.. J. Clin. Invest. 30: 616 (1951).
- Mancini, G., et. al. Immunochemistry 2:235 (1965).
- Singer, J.M., et. al.. Am. J. Med 21: 888 (1956).
- Fischer, C.L., Gill, C.W.. In Serum Protein Abnormalities. Boston, Little, Brown and Co., (1975).
- Darooghegi M, M; Milajerdi, Aa; .et.al (2019). Garlic Supplementation Reduces Circulating C-reactive Protein, Tumor Necrosis Factor, and Interleukin-6 in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. The Journal of Nutrition; 00:1–14.

- Mazidi, M; Rezaie, P; et.al (2018). Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. Archives of Medical Science, 14(4), 707–716.

 **ATLAS Medical GmbH**  
**Ludwig-Erhard Ring 3**  
**15827 Blankenfelde-Mahlow**  
**Germany**  
**Tel: +49 - 33708 – 3550 30**  
**Email: [Info@atlas-medical.com](mailto:Info@atlas-medical.com)**  
**Website: [www.atlas-medical.com](http://www.atlas-medical.com)**

**PPI2327A01**

**Rev B (10.02.2024)**

|                                                                                       |                                                     |                                                                                       |                                    |
|---------------------------------------------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------|
|    | Catalogue Number                                    |    | Temperature limit                  |
|    | In Vitro diagnostic medical device                  |    | Caution                            |
|    | Contains sufficient for <n> tests and Relative size |    | Consult instructions for use (IFU) |
|    | Batch code                                          |    | Manufacturer                       |
|    | Fragile, handle with care                           |    | Use-by date                        |
|    | Manufacturer fax number                             |    | Do not use if package is damaged   |
|    | Manufacturer telephone number                       |    | Date of Manufacture                |
|  | Keep away from sunlight                             |  | Keep dry                           |
|  | Positive control                                    |  | Negative control                   |